# data[].attributes.headline
Team #5 Johnson & Johnson Financial Ratios Excel File

# data[].attributes.subject
Team #5 Johnson & Johnson Financial Ratios Excel File

# data[].attributes.body
Johnson & Johnson's first First-Aid Kit
This was made for the New York City and Hudson River Railroad companies. The idea for a first aid kit came from a discussion Robert Wood Johnson had with a railroad surgeon about if the railroad engineers got hurt while traveling (usually away from everything) they had no way of taking care of each other in the case of an emergency.

# data[].attributes.headline
This article by Robert Cyran in the New York Times (June 2, 2016) discusses the desire of some investor that Johnson & Johnson break up into smaller companies instead of being one giant conglomerate.  The one thing that investors do not like about JNJ is that their returns to shareholders are low/mediocre.  While many investors do not like this the consistency of JNJ year or year is what draws people to them as a solid long term investment.  The problem arises when investors are looking to make bigger returns faster which is something you do not see with JNJ.  

# data[].attributes.subject
This article by Robert Cyran in the New York Times (June 2, 2016) discusses the desire of some investor that Johnson & Johnson break up into smaller companies instead of being one giant conglomerate.  The one thing that investors do not like about JNJ is that their returns to shareholders are low/mediocre.  While many investors do not like this the consistency of JNJ year or year is what draws people to them as a solid long term investment.  The problem arises when investors are looking to make bigger returns faster which is something you do not see with JNJ.  

# data[].attributes.attachment_link.readable_text
Johnson & Johnson weighs heavy. The bulging health care conglomerate is swallowing the hair-care company Vogue International for $3.3 billion in defiance of calls to break up. Johnson & Johnson's $312 billion market value makes it a hard target for activists. Yet its size has created ailments, including poor merger-and-acquisition activity and mediocre shareholder returns.

Over the last decade shareholders have largely come to the conclusion that pharmaceutical firms should focus on developing medicines. After all, there's little in common between using science to discover a cure for Alzheimer's and selling shampoo. That has led Abbott Laboratories to spin off the pharmaceutical division AbbVie; Pfizer and Merck each to sell their consumer-goods business;and GlaxoSmithKline to divest nutritional drinks. The results have been largely favorable to investors too, because the cash thrown off by consumer goods companies is coveted by yield-starved investors.

Johnson & Johnson has resisted the trend. About one-fifth of its revenue comes from selling consumer health and beauty products such as Band-Aids and Listerine. Over 40 percent comes from cutting-edge drugs, and the rest from medical devices. The diversity may produce relatively steady results, but investors aren't terribly appreciative of the fish-fowl hybrid. The company is valued at about 11.5 times estimated earnings before interest, taxes, depreciation and amortization, or Ebitda, over the next 12 months. That's lower than the multiples attached to the consumer goods maker Colgate and the drug maker Eli Lilly, which trade between 14 and 15 times Ebitda, and the medical device firm Medtronic, at 12.5 times.

This has not escaped investors. Artisan Partners tried to pressure Johnson & Johnson to split earlier this year. However, Artisan owned well under 1 percent of its stock; combined with Johnson and Johnson's scattered investor base, the activist had almost no power to battle its giant target.

The company's girth comes at a cost. The drug business is faring well, but the other divisions are not. The consumer-goods unit's margins are below rivals' and some of its factories still operate under regulatory oversight from the Food and Drug Administration after a wave of product recalls a few years ago. The medical device division's profits have been essentially stagnant since 2010 despite buying a rival, Synthes, for around $20 billion five years ago. Slimming down, or even splitting into three, would serve Johnson & Johnson well.

# data[].attributes.attachment_link.description
Johnson & Johnson weighs heavy. The bulging health care conglomerate is swallowing the hair-care company Vogue International for $3.3 billion in defiance of calls to break up. Johnson & Johnson's $312 billion market value makes it a hard target for activists. Yet its size has created ailments, including poor merger-and-acquisition activity and mediocre shareholder returns.

# data[].attributes.body
Johnson & Johnson - 8 Things
This article gives a few interesting facts about Johnson & Johnson talking about the number of subsidiaries, talking about their adjusted EPS ( 31 straight years of increasing), and a few other tidbits of information that shows JNJ in an interesting way.

# data[].attributes.attachment_link.readable_text
Healthcare conglomerate ( Johnson & Johnson NYSE:JNJ) is arguably the mantelpiece healthcare company all investors look up to.

With the exception of Novartis, which is currently dueling neck-and-neck with J&J for the highest market valuation among healthcare stocks, Johnson & Johnson is the unrivaled company that tends to set the tone through the sector come earnings season. As one of the largest healthcare companies, it's also looked up to by income-seekers and risk-averse investors who count on J&J's above-average dividend yield; its steady profits, which derive from its three business segments (consumer health, medical devices, and pharmaceuticals); and its lack of volatility. Johnson & Johnson shareholders get the luxury of a good night's sleep each night, which isn't something select biotech investors can attest to.

But there's so much more to Johnson & Johnson that you may not realize. Here are eight things you may not already know about J&J that could give you an even greater appreciation of the company and what it does for investors.

1. J&J consists of more than 250 subsidiaries
As I mentioned, Johnson & Johnson is built around three business segments -- a slower-growing consumer-health segment, a currently slower-growing medical-device segment that has a solid long-term outlook, and a fast-growing pharmaceutical segment. While these businesses are delivering operational growth, J&J has, throughout history, not been shy about purchasing other companies to increase its product portfolio and profitability.

In actuality, Johnson & Johnson consists of more than 250 subsidiaries among its three business segments, and it operates in more than 60 countries. With so many subsidiaries and such a diverse set of healthcare products, it's not hard to see why J&J's growth has been so steady for the past couple of decades.

2. J&J has increased its adjusted EPS for 31 straight years
Adding to the point, Johnson & Johnson has also delivered an incredible streak for its investors of growing its adjusted earnings per share, or EPS, for 31 consecutive years. By adjusted, I mean J&J strips out the one-time factors that can cause fluctuations in profits from year to year, such as currency moves, divestments, acquisitions, and one-time tax benefits, so investors can have a true apples-to-apples comparison. What this should imply to investors is that J&J's management is not only dedicated to growing the company, but that it's also incredibly efficient and competent at doing so.

3. Only six companies have a longer streak of raising their dividend than J&J
Many investors may be familiar with an elite class of just over four dozen dividend-paying stocks known as Dividend Aristocrats, which have increased their dividend for a minimum of 25 straight years. J&J is part of this elite class, but it's so much more.

Out of four-plus-dozen companies that have regularly increased their dividend for the past 25-plus years, only six companies can boast a longer continuous streak than Johnson & Johnson's current 53-year streak. And with a payout ratio of just 50%, chances are J&J has many more years of dividend increases left in its tank.

4. J&J is one of the world's largest corporate donors
As one of the world's largest companies, J&J is also regularly one of the world's largest corporate donors. Philanthropy.com notes that Johnson & Johnson gave a little more than $157 million to charity in 2013, a 20% increase from the previous year.

Specifically, Johnson & Johnson was noted for giving tens of millions of dollars to partners around the world to help research and eliminate the transmission of HIV from mother to infant, and also to help fund the development of professional healthcare workers, such as nurses and midwives, around the globe.

5. J&J has had only nine company leaders since being founded in 1886
One common sign of a great company is a cohesive management team that investors can trust -- and that's exactly what you get with J&J.

Oftentimes, the greatest companies tend to have CEOs that take the reins and hang around for extended periods. In J&J's case, the company has had just seven CEOs since it moved to the NYSE more than seven decades ago. In total, it's only had nine leaders since being founded 129 years ago! Current CEO Alex Gorsky has been with J&J or its subsidiaries for 23 of the past 27 years. This is the epitome of a cohesive management team that maintains focus.

6. It had the eighth-largest R&D budget in 2013
Researching dozens upon dozens of new drugs isn't cheap, but Johnson & Johnson is up to the task of paying exorbitant amounts of money to keep its fast-growing pharmaceutical segment churning out huge profits for investors.

According to Fortune, in 2013 Johnson & Johnson spent a whopping $8.2 billion on research and development, which was good enough for the eighth-largest R&D budget in the world. At 11.5% of its total revenue, that might sound like a lot, but it's been hard to argue with the results. Between 2009 and today, J&J brought 14 new molecular entities, or NMEs, to market, of which seven have reached blockbuster status ($1 billion-plus in annual sales). Earlier this year, J&J outlined plans to file for approval for 10 NMEs that it believes will become blockbusters by the end of the decade.

7. It also boasts one of the biggest advertising budgets in the world
In addition to spending a small fortune on R&D, Johnson & Johnson isn't shy about promoting its consumer health or pharmaceutical products.

Last year, Johnson & Johnson's annual filing listed its advertising spending at a whopping $2.6 billion, which is good enough to put it among the world's largest advertisers. J&J has the luxury of promoting its brands so aggressively because it's generated between $11.4 billion and $14.8 billion in free cash flow in each of the past nine years. With a robust advertising budget comes strong brand recognition and the potential to forge emotional connections with consumers vis-a-vis increased impressions.

8. One of only three AAA-rated publicly-traded companies
Finally, among the more than 7,100 publicly-listed companies, a mere three boast the highest "AAA" credit rating Standard & Poor's issues. Johnson & Johnson is one of those companies.

What does J&J's AAA rating imply? Only that one of the most-recognized credit agencies in the world believes that J&J has a positive long-term outlook and the tools necessary to easily manage its debt. Let me remind you that Standard & Poor's was the agency that downgraded the United States' AAA credit rating one notch to AA+ back in 2011.

Long story short, if you've been wondering why everyone is always touting Johnson & Johnson as such a great company to own over the long run, maybe these eight points will help to finally explain it.

# data[].attributes.attachment_link.title
8 Things You Probably Don't Know About Johnson & Johnson

# data[].attributes.attachment_link.description
Healthcare conglomerate ( Johnson & Johnson NYSE:JNJ) is arguably the mantelpiece healthcare company all investors look up to. With the exception of Novartis, which is currently dueling neck-and-neck with J&J for the highest market valuation among healthcare stocks, Johnson & Johnson is the unrivaled company that tends to set the tone through the sector come earnings season.

# data[].attributes.headline
Team #5 Johnson & Johnson Powerpoint PResentation

# data[].attributes.subject
Team #5 Johnson & Johnson Powerpoint PResentation

# data[].attributes.body
This video gives a great overview of the history of Johnson & Johnson and how their Credo was created. The company has also people their customers and employees ahead of stockholders. It is this Credo and desire to do the right thing that may frustrate investors. Johnson & Johnson would rather send supplies and money to a disaster area than to make sure that they have a high dividend to return on investment for their shareholders. This is very unusual in business, most companies are looking to make a higher profits instead of doing what is right by people.

# data[].attributes.attachment_link.entities[].name
History of Leadership at Johnson & Johnson

# data[].attributes.attachment_link.entities[].name
DePuy Synthes Companies of Johnson & Johnson

# data[].attributes.attachment_link.title
Johnson & Johnson: Our History, Our Mission

# data[].attributes.attachment_link.description
Johnson & Johnson 125th Anniversary Video, celebrating our history, our products and our community. Our aspiration as a company is to care for the world, one person at a time. Our YouTube channel provides you an unprecedented look behind the scenes at Johnson & Johnson, spotlighting the people, stories and causes that inspire us to care.

# data[].attributes.headline
Team #5 Johnson & Johnson Executive Summary

# data[].attributes.subject
Team #5 Johnson & Johnson Executive Summary

# data[].attributes.body
2015 Investor Fact Sheet from Johnson & Johnson - Why JNJ feels you should invest into their company.  It shows the consistency that everyone talks about which is what Johnson & Johnson wants their current or potential investors to see.
http://files.shareholder.com/downloads/JNJ/2591240610x0x856393/1267DC95-99FA-47D8-81AA-A0A855C129E8/JNJ_2015_Investor_Fact_Sheet_v5.pdf

# data[].attributes.headline
A day in the life of brand managers at the Johnson & Johnson Family of Consumer Companies

# data[].attributes.subject
A day in the life of brand managers at the Johnson & Johnson Family of Consumer Companies

# data[].attributes.body
This video shows the positive attitude of JNJ employees and their drive to continue to better their products. This is a good trait for a company to have when being looked at by investors.

# data[].attributes.attachment_link.title
A day in the life of brand managers at the Johnson & Johnson Family of Consumer Companies

# data[].attributes.headline
Is the Johnson & Johnson stock valuable?

# data[].attributes.subject
Is the Johnson & Johnson stock valuable?

# data[].attributes.body
This video discusses JNJ's track record, long term PE ratio, its quality management team with family values, and weathering the market fall of '08. It also talks about its 31 years of adjusted earnings increase and 52 years of dividend increase. According to these two experts they recommend buying stock in JNJ for a long term investment.

# data[].attributes.attachment_link.entities[].name
Marnus Broodryk Ichimoku Stock Option Trade Review

# data[].attributes.attachment_link.title
Is the Johnson & Johnson stock valuable?

# data[].attributes.attachment_link.description
Celebrated fund managers, Sean Aston and Bryan Rudd from Anchor Capital join CNBC Africa's Gugulethu Cele to talk about one of the most recognisable household names in baby care products, Johnson & Johnson. Is it a buy, hold or sell for this stock?

# data[].attributes.headline
J&J Global Public Health Leaders Recap Healthcare Themes from Davos 2016

# data[].attributes.subject
J&J Global Public Health Leaders Recap Healthcare Themes from Davos 2016

# data[].attributes.body
This video talks about the world forum that took place in Davos with the stake holders and policy makers. They discussed being prepared for the next pandemic and that public and private sectors will need to join in the collaboration. They also made agreements with stake holders to meet again and take on the challenges that lay ahead.

# data[].attributes.attachment_link.title
J&J Global Public Health Leaders Recap Healthcare Themes from Davos 2016

# data[].attributes.attachment_link.description
Johnson & Johnson Global Public Health leaders Jaak Peeters and Alan Tennenberg recap healthcare themes and conversations from Davos 2016. Our aspiration as a company is to care for the world, one person at a time. Our YouTube channel provides you an unprecedented look behind the scenes at Johnson & Johnson, spotlighting the people, stories and causes that inspire us to care.

# data[].attributes.body
This is Johnson & Johnson's 10K report for 2015.